Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study
- B. Douglas Smith
- , Tim H. Brümmendorf
- , Gail J. Roboz
- , Carlo Gambacorti-Passerini
- , Aude Charbonnier
- , Andrea Viqueira
- , Eric Leip
- , Simon Purcell
- , Erinn Hoag Goldman
- , Francis Giles
- , Thomas Ernst
- , Andreas Hochhaus
- , Gianantonio Rosti
- Johns Hopkins Oncology Center
- RWTH Aachen University
- Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD)
- Joan and Sanford I. Weill Department of Medicine
- University of Milano-Bicocca
- Institut Paoli Calmettes
- Pfizer Inc.
- Pfizer Regenerative Medicine
- Developmental Therapeutics LLC
- Jena University Hospital
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”
Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review
3
Citations
(Scopus)